SRPT News and Press, Sarepta Therapeutics Inc. From 01/12/26

2026-01-12 14:36:00 ET Sarepta Therapeutics, Inc. (SRPT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healt...

2026-01-12 12:42:52 ET More on Sarepta Therapeutics Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 FDA Duchenne Failure Hits Sarepta Ami...

Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025 Preliminary PMO net product reve...

San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) concerning whether certain officers and directors breached their fiduciary ...

2026-01-10 04:12:54 ET Shares of Duchenne muscular dystrophy concern Capricor Therapeutics, Inc. ( CAPR ) more than tripled on December 3, 2025 after releasing seemingly approvable Phase 3 disease progression data. The HOPE-3 results, including a 54% slowing of upper limb perfor...

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical tria...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 12, 2026 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Foll...

2025-12-17 06:48:20 ET Thesis The big news yesterday is that the U.S. Department of Health and Human Services ((HHS)) has made the decision to add Duchenne muscular dystrophy (DMD) to the recommended newborn screening panel. Now I see this as being great news for Sarepta Therape...

2025-12-16 11:38:00 ET More on Sarepta Therapeutics Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation Sare...

2025-12-11 07:46:21 ET More on Sarepta Therapeutics Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation Sare...